Table 1.
Baseline characteristics are displayed for the primary data from the PANDEMIC registry, and all individual data, respectively. The values are presented as the median with interquartile range (IQR) or as frequencies (n) and relative proportion of all the available valid data sets (%). Critical disease according to LEOSS (Lean European Open Survey on SARS-CoV-2 infected patients) registry criteria; ECMO extracorporeal membrane oxygenation; mRS modified Rankin Scale; COVID-19 coronavirus disease 2019; ICH intracranial hemorrhage; IPH intraparenchymal hemorrhage; SAH subarachnoid hemorrhage; IVH intraventricular hemorrhage; EDH/SDH epidural/subdural hematoma; HT/PH of IS hemorrhagic transformation/parenchymal hematoma of ischemic stroke; SVT sinus venous thrombosis; INR international normalized ratio and aPTT activated partial thromboplastin time.
| Baseline Characteristics | PANDEMIC Registry (n = 34) | All Individual Patient Data (n = 142) | |
|---|---|---|---|
| Age (years), median (IQR) | 64.0 (57.0–76.0) | 61.0 (53.8–71) | |
| Female, n (%) | 5/34 (14.7) | 49/142 (34.5) | |
| Critical disease (LEOSS), n (%) | 22/34 (64.7) | 81/128 (63.3) | |
| ECMO, n (%) | 12/34 (35.3) | 21/101 (20.8) | |
| Anticoagulation, n (%) | 32/34 (94.1) | 86/104 (82.7) | |
| Time from COVID-19 diagnosis to ICH diagnosis (days), median (IQR) | 21.0 (15.5–31.3) | 15 (8.0–22.5) | |
| Non-neurological symptoms | Fever, n (%) | 3/34 (8.8) | 50/119 (42.0) |
| Respiratory symptoms, n (%) | 20/34 (58.8) | 89/116 (76.7) | |
| Myalgia/arthralgia, n (%) | 3/34 (8.8) | 10/119 (8.4) | |
| Malaise, n (%) | 3/34 (8.8) | 12/119 (10.1) | |
| Neurological symptoms | Focal neurological deficits, n (%) | 6/34 (17.6) | 26/122 (21.3) |
| Altered level of consciousness, n (%) | 20/34 (58.8) | 64/128 (50.0) | |
| Encephalopathy, n (%) | 1/34 (2.9) | 5/123 (4.1) | |
| Headache, n (%) | - | 19/123 (15.5) | |
| Anisocoria, n (%) | 12/34 (35.3) | 29/124 (23.4) | |
| Seizure, n (%) | - | 8/127 (6.3) | |
| ICH | IPH, n (%) | 20/34 (58.8) | 68/142 (47.9) |
| SAH, n (%) | 16/34 (47.1) | 44/142 (31.0) | |
| SDH/EDH, n (%) | 4/34 (11.8) | 8/142 (5.6) | |
| Microbleeds, n (%) | 6/34 (17.6) | 25/130 (19.2) | |
| Lobar microbleeds n (%) | - | 1/25 (4.0) | |
| Deep microbleeds n (%) | 2/6 (33.3) | 2/25 (8.0) | |
| Mixed location microbleeds n (%) | 4/6 (66.6) | 22/25 (88.0) | |
| Not given n (%) | - | - | |
| IVH, n (%) | 4/34 (11.8) | 7/142 (4.9) | |
| HT/PH of IS, n (%) | - | 3/142 (2.1) | |
| SVT with hemorrhage, n (%) | - | 4/142 (2.8) | |
| Other, n (%) | - | - | |
| Multilocular ICH, not further specified, n (%) | - | - | |
| Laboratory values | White blood cells (×109/L), median (IQR) | 20.3 (15.0–26.8) | 15.8 (12.5–22.2) |
| Platelet count (×109/L), median (IQR) | 121.5 (70.5–185) | 176.0 (97.3–261.5) | |
| C-reactive protein (mg/L), median (IQR) | 340.0 (231.0–402.0) | 220.0 (54.5–340.0) | |
| INR, median (IQR) | 1.4 (1.2–1.8) | 1.3 (1.1–1.6) | |
| aPTT (s), median (IQR) | 58.0 (44.0–75.0) | 58 (38.8–68.0) | |
| D-dimer (mg/L), median (IQR) | 17.9 (7.8–23.9) | 6.8 (2.4–18.0) | |
| mRS | 0, n (%) | - | 5/118 (4.2) |
| 1, n (%) | 1/32 (3.1) | 2/118 (1.7) | |
| 2, n (%) | - | 3/118 (2.5) | |
| 3, n (%) | 2/32 (6.3) | 3/118 (2.5) | |
| 4, n (%) | 5/32 (15.6) | 8/118 (6.8) | |
| 5, n (%) | 3/32 (9.4) | 9/118 (7.6) | |
| 6, n (%) | 21/32 (65.6) | 88/118 (74.6) | |
| Death under palliative care, n (%) | 13/24 (54.2) | 34/101 (33.7) | |
| Mortality | Total, n (%) | 21/33 (64) | 88/119 (73.9) |
| IPH, n (%) | 13/20 (65) | 44/68 (64.7) | |
| SAH, n (%) | 12/16 (75.0) | 29/44 (65.9) | |
| SDH/EDH, n (%) | 4/4 (100.0) | 7/8 (87.5) | |
| Microbleeds, n (%) | 3/6 (50.0) | 13/25 (52.0) | |
| Lobar microbleeds n (%) | - | - | |
| Deep microbleeds n (%) | 2/3 | 2/13 | |
| Mixed location microbleeds n (%) | 1/3 | 11/13 | |
| Not given n (%) | - | - | |
| IVH, n (%) | 2/4 (50.0) | 3/7 (42.9) | |
| HT/PH of IS, n (%) | - | 3/3 (100%) | |
| SVT with hemorrhage, n (%) | - | 4/4 (100%) | |
| Other, n (%) | - | - | |
| Multilocular ICH, not further specified, n (%) | - | - | |